Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cumulative risk of developing a new symptom in patients with primary biliary cholangitis and its impact on prognosis.
Kimura N, Setsu T, Arao Y, Sakai N, Watanabe Y, Abe H, Kamimura H, Sakamaki A, Yokoo T, Kamimura K, Tsuchiya A, Osaki A, Igarashi K, Waguri N, Yanagi M, Takahashi T, Sugitani S, Kobayashi Y, Takamura M, Yoshikawa A, Ishikawa T, Yoshida T, Watanabe T, Bannai H, Kubota T, Funakoshi K, Wakabayashi H, Kurita S, Ogata N, Watanabe M, Mita Y, Mori S, Sugiyama M, Miyajima T, Takahashi S, Sato S, Ishizuka K, Ohta H, Aoyagi Y, Terai S. Kimura N, et al. Among authors: sugiyama m. JGH Open. 2022 Jul 15;6(8):577-586. doi: 10.1002/jgh3.12789. eCollection 2022 Aug. JGH Open. 2022. PMID: 35928695 Free PMC article.
Changes in disease characteristics of primary biliary cholangitis: An observational retrospective study from 1982 to 2016.
Takamura M, Matsuda Y, Kimura N, Takatsuna M, Setsu T, Tsuchiya A, Osaki A, Waguri N, Yanagi M, Takahashi T, Sugitani S, Kobayashi Y, Yoshikawa A, Ishikawa T, Yoshida T, Watanabe T, Bannai H, Kubota T, Funakoshi K, Wakabayashi H, Kurita S, Ogata N, Watanabe M, Mita Y, Mori S, Sugiyama M, Miyajima T, Takahashi S, Sato S, Ishizuka K, Ohta H, Aoyagi Y, Terai S; Niigata PBC Study Group. Takamura M, et al. Among authors: sugiyama m. Hepatol Res. 2021 Feb;51(2):166-175. doi: 10.1111/hepr.13586. Epub 2020 Nov 28. Hepatol Res. 2021. PMID: 33126288
Absence of pretreatment markers that predict the emergence of YMDD mutants during lamivudine treatment--the results of a prospective multi-center study.
Yano M, Ohkoshi S, Suzuki K, Ito S, Wakabayashi H, Sugiyama M, Watanabe T, Maeda H, Hatakeyama SA, Hatano T, Kobayashi Y, Takei S, Kohjiro H, Tsuboi Y, Takahashi T, Ishikawa T, Kamimura T, Ichida T, Aoyagi Y. Yano M, et al. Among authors: sugiyama m. Hepatogastroenterology. 2006 Jan-Feb;53(67):124-7. Hepatogastroenterology. 2006. PMID: 16506390
Successful treatment with lamivudine may correlate with reduction of serum ferritin levels in the patients with chronic hepatitis and liver cirrhosis type B.
Ohkoshi S, Yoshimura A, Yamamoto S, Yano M, Kurita S, Yamazaki K, Aoki YH, Yamagiwa S, Wakabayashi H, Sugiyama M, Takahashi T, Ishikawa T, Matsuda Y, Ichida T, Kamimura T, Aoyagi Y. Ohkoshi S, et al. Among authors: sugiyama m. Hepatol Int. 2008 Sep;2(3):382-7. doi: 10.1007/s12072-008-9084-z. Epub 2008 Jul 25. Hepatol Int. 2008. PMID: 19669269 Free PMC article.
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K, Yasuda Y, Ando M, Onoue T, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Hase T, Nishio N, Mori S, Shimokata T, Sano T, Niimi K, Yoshikawa N, Akamatsu S, Ando Y, Akiyama M, Sone M, Ishii M, Arima H. Kobayashi T, et al. Among authors: sugiyama m. Cancer Immunol Immunother. 2024 Jun 4;73(8):146. doi: 10.1007/s00262-024-03733-2. Cancer Immunol Immunother. 2024. PMID: 38833157 Free PMC article.
2,491 results